Redeye updates its estimates following Pagero’s Q2 2023 report, which was in line on the ARR and sales side, while margins were somewhat weaker than anticipated. On the other hand, Pagero is in an investment phase to gain market share globally and is thus investing heavily in its technology and organisation, and margin improvement will likely come over time as the volumes scale naturally. Q2 2023 marked the second quarter in a row where the growth was above 30%, suggesting good business momentum.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/